CN106666738A - 一种用于改善人体代谢紊乱状态的组合物及其制备方法 - Google Patents
一种用于改善人体代谢紊乱状态的组合物及其制备方法 Download PDFInfo
- Publication number
- CN106666738A CN106666738A CN201611146933.7A CN201611146933A CN106666738A CN 106666738 A CN106666738 A CN 106666738A CN 201611146933 A CN201611146933 A CN 201611146933A CN 106666738 A CN106666738 A CN 106666738A
- Authority
- CN
- China
- Prior art keywords
- parts
- capsule
- compositionss
- dietary fiber
- aloe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 208000030159 metabolic disease Diseases 0.000 title abstract description 4
- 239000002775 capsule Substances 0.000 claims abstract description 67
- 241001116389 Aloe Species 0.000 claims abstract description 38
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 38
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 36
- 102000038379 digestive enzymes Human genes 0.000 claims abstract description 29
- 108091007734 digestive enzymes Proteins 0.000 claims abstract description 29
- 235000018291 probiotics Nutrition 0.000 claims abstract description 29
- 239000006041 probiotic Substances 0.000 claims abstract description 28
- 230000008901 benefit Effects 0.000 claims abstract description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 32
- 241000894006 Bacteria Species 0.000 claims description 29
- 230000000529 probiotic effect Effects 0.000 claims description 24
- 230000004060 metabolic process Effects 0.000 claims description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 21
- 239000002994 raw material Substances 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 19
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 239000008103 glucose Substances 0.000 claims description 11
- 235000005979 Citrus limon Nutrition 0.000 claims description 10
- 244000131522 Citrus pyriformis Species 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 108010010803 Gelatin Proteins 0.000 claims description 10
- 238000010521 absorption reaction Methods 0.000 claims description 10
- 229940088598 enzyme Drugs 0.000 claims description 10
- 239000008273 gelatin Substances 0.000 claims description 10
- 229920000159 gelatin Polymers 0.000 claims description 10
- 235000019322 gelatine Nutrition 0.000 claims description 10
- 235000011852 gelatine desserts Nutrition 0.000 claims description 10
- 235000012424 soybean oil Nutrition 0.000 claims description 10
- 239000003549 soybean oil Substances 0.000 claims description 10
- 108090001060 Lipase Proteins 0.000 claims description 9
- 102000004882 Lipase Human genes 0.000 claims description 9
- 239000004367 Lipase Substances 0.000 claims description 9
- 239000007766 cera flava Substances 0.000 claims description 9
- 235000019421 lipase Nutrition 0.000 claims description 9
- 239000004382 Amylase Substances 0.000 claims description 8
- 102000013142 Amylases Human genes 0.000 claims description 8
- 108010065511 Amylases Proteins 0.000 claims description 8
- 108010059892 Cellulase Proteins 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 108091005804 Peptidases Proteins 0.000 claims description 8
- 235000019418 amylase Nutrition 0.000 claims description 8
- 229940106157 cellulase Drugs 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- 238000004806 packaging method and process Methods 0.000 claims description 8
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 7
- 229930091371 Fructose Natural products 0.000 claims description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 7
- 239000005715 Fructose Substances 0.000 claims description 7
- 108010051210 beta-Fructofuranosidase Proteins 0.000 claims description 7
- 235000011073 invertase Nutrition 0.000 claims description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 7
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000000377 silicon dioxide Substances 0.000 claims description 7
- 235000012239 silicon dioxide Nutrition 0.000 claims description 7
- 239000004408 titanium dioxide Substances 0.000 claims description 7
- XINCECQTMHSORG-UHFFFAOYSA-N Isoamyl isovalerate Chemical compound CC(C)CCOC(=O)CC(C)C XINCECQTMHSORG-UHFFFAOYSA-N 0.000 claims description 6
- 244000199866 Lactobacillus casei Species 0.000 claims description 6
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 6
- 229940017800 lactobacillus casei Drugs 0.000 claims description 6
- 241001608472 Bifidobacterium longum Species 0.000 claims description 5
- 244000068988 Glycine max Species 0.000 claims description 5
- 235000010469 Glycine max Nutrition 0.000 claims description 5
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 5
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 5
- 102000035195 Peptidases Human genes 0.000 claims description 5
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 5
- 235000010987 pectin Nutrition 0.000 claims description 5
- 229920001277 pectin Polymers 0.000 claims description 5
- 239000001814 pectin Substances 0.000 claims description 5
- 235000019833 protease Nutrition 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 4
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 4
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 4
- 102000016679 alpha-Glucosidases Human genes 0.000 claims description 4
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 4
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 241000186000 Bifidobacterium Species 0.000 claims description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 3
- 235000019419 proteases Nutrition 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 abstract description 11
- 201000001421 hyperglycemia Diseases 0.000 abstract description 11
- 230000036541 health Effects 0.000 abstract description 9
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 6
- 230000007661 gastrointestinal function Effects 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 5
- 230000000968 intestinal effect Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 238000013459 approach Methods 0.000 abstract description 2
- 239000002075 main ingredient Substances 0.000 abstract 2
- 241000196324 Embryophyta Species 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 230000001473 noxious effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 29
- 210000004369 blood Anatomy 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 23
- 230000035611 feeding Effects 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 230000036772 blood pressure Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 235000001727 glucose Nutrition 0.000 description 11
- 235000011187 glycerol Nutrition 0.000 description 9
- 235000012054 meals Nutrition 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000010172 mouse model Methods 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 108010028554 LDL Cholesterol Proteins 0.000 description 7
- 239000003292 glue Substances 0.000 description 7
- 150000002304 glucoses Chemical class 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 108010089934 carbohydrase Proteins 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 235000005955 light diet Nutrition 0.000 description 3
- 229960001712 testosterone propionate Drugs 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- 241000790917 Dioxys <bee> Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 241000256844 Apis mellifera Species 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000003906 autonomic nervous system functioning Effects 0.000 description 1
- 235000002201 avitaminosis Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- -1 starch Together Chemical class 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 235000020795 whole food diet Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01004—Cellulase (3.2.1.4), i.e. endo-1,4-beta-glucanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01108—Lactase (3.2.1.108)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/147—Helveticus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/513—Adolescentes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/529—Infantis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Abstract
本发明公开了保健食品领域的一种用于改善人体代谢紊乱状态的组合物及其制备方法。该组合物以芦荟胶囊、消化酶、益生菌、膳食纤维为主要成分,并公开了其各组合物的主要组成成分及其制备方法,采用“3+3+3”模式连续服用,即前三日服用芦荟胶囊,排毒润肠;中三日服用消化酶和膳食纤维,清除宿便、调节肠道环境;后三日服用益生菌和膳食纤维,定植有益菌、改善胃肠功能。与现有技术相比,本发明具有以下优点:从调节肠胃功能途径出发,改善人体代谢紊乱状态,降低高血压、高血糖和高血脂,副作用小,高效安全,可短期内有效改善“三高”亚健康人群的胃肠功能,降低“三高”的同时还可以起到保健的作用,改善身体亚健康状态。
Description
技术领域
本发明涉及保健食品领域,具体涉及一种用于改善人体代谢紊乱状态的组合物及其制备方法。
背景技术
高血压、高血脂、高血糖等代谢紊乱状态是严重危害健康的人体指标。美国著名内分泌专家Reaven将高血糖中的胰岛素抵抗、高胰岛素血症、糖耐量异常、高血脂中的高甘油三脂血症和高血压统称称为“X综合征”,即现在医学界一般说的代谢综合征。心脑血管疾病具有“发病率高、致残率高、死亡率高、复发率高,并发症多”形成“四高一多”的特点,目前,我国心脑血管疾病患者已经超过2.7亿人,高血脂可以引起血管栓塞;高血压可以引起脑出血和脑血管破裂;高血糖可以引起糖尿病。世界卫生组织曾经明确提出,防止心血管病的第一道防线就是减少“三高”和控制“三高”。由此可见,改善人体的代谢紊乱状态,对于人类的健康而言是非常重要的。
发明内容
针对上述问题,本发明提出一种用于改善人体代谢紊乱状态的组合物及其制备方法,利用芦荟胶囊、消化酶、益生菌、膳食纤维的组合服用,达到改善胃肠功能,调节人体代谢平衡。
本发明是通过以下技术方案解决上述技术问题的:
一种用于改善人体代谢紊乱状态的组合物,组合物包括:芦荟胶囊、消化酶、益生菌、膳食纤维。
进一步,为使各组合物更好的发挥其综合功效,其服用方法为前三日服用芦荟胶囊、中三日服用消化酶和膳食纤维,后三日服用益生菌和膳食纤维。
进一步,芦荟胶囊包括以下重量份数的原料:芦荟粉3~5份;大豆油0.5~1份;蜂蜡0.1~0.5份;二氧化钛0.1~0.5份;柠檬黄0.2~0.4份;明胶0.5~0.7份;甘油0.2~0.5份。
进一步,芦荟胶囊包括以下重量份数的原料:芦荟粉5份;大豆油0.5份;蜂蜡0.3份;二氧化钛0.2份;柠檬黄0.2份;明胶0.7份;甘油0.4份。
进一步,消化酶包括以下质量份数的原料:淀粉酶4~7份;蛋白酶5~9份;乳糖酶6~10份;蔗糖酶6~10份;麦芽糖酶11~14份;脂肪酶13~15份;纤维素酶20~23份;果糖1~3份;葡萄糖1~2.5份;硫酸镁0.2~0.5份;二氧化硅0.3~0.5份;柠檬酸0.1~0.3份;苹果香精0.2~0.4份。
进一步,消化酶包括以下重量份数的原料:淀粉酶7份;蛋白酶9份;乳糖酶10份;蔗糖酶10份;麦芽糖酶13份;脂肪酶15份;纤维素酶22份;果糖3份;葡萄糖2.5份;硫酸镁0.3份;二氧化硅0.3份;柠檬酸0.2份;苹果香精0.3份。
进一步,五种益生菌为嗜酸乳杆菌、罗伊氏乳杆菌、干酪乳杆菌、瑞士乳杆菌、乳双歧杆菌、长双歧杆菌、青春双歧杆菌和婴儿双歧杆菌中任五种,其质量份数均为3~5份,益生菌活菌量为109~1011CFU/g。
进一步,益生菌包括以下重量份数的原料:干酪乳杆菌4份;瑞士乳杆菌4份;乳双歧杆菌4份;长双歧杆菌4份;青春双歧杆菌4份。
进一步,膳食纤维由以下重量份数的原料混合而成:大豆膳食纤维5~10份;麦麸4~7份;苹果果胶2~3份。
一种制备上述用于改善人体代谢紊乱状态的组合物的方法,包括如下步骤:
(1)原料混合物制备:分别将各组合物中原料按配方依次置于无菌混合机内,混合均匀,即得所述原料混合物;
(2)胶囊制备:使用全自动胶囊充填机充填步骤(1)中所述原料混合物,填充好的胃溶胶囊使用胶囊抛光机清除吸附在胶囊外壁上的细粉,使胶囊光洁,无菌下包装,即制成所述组合物胶囊。
芦荟胶囊是以芦荟为主要原料,运用现代生物技术分离提取芦荟中的营养成分,制成芦荟凝胶冻干粉,使用先进生产工艺制成的软胶囊天然食品。由于芦荟中所含的芦荟素能够增加大肠液的分泌,增加脂肪酶的活性,恢复失调的大肠自律神经功能,使芦荟成为古今中外治疗便秘最有效的药物,即使非常严重的便秘,服用芦荟后,也能在8~12小时内通便。
消化酶是参与消化的酶的总称,包括淀粉酶、蛋白酶、乳糖酶、蔗糖酶、麦芽糖酶、脂肪酶、纤维素酶等。消化酶可促进食物中糖、脂肪、蛋白质等营养成分水解,使大分子物质变为小分子物质,以便被人体吸收利用。消化酶影响着营养物质的消化和吸收,缺乏消化酶会造成低蛋白血症、脂肪性腹泻、脂溶性维生素缺乏、内分泌紊乱等。
益生菌是一类对宿主有益的活性微生物,是定植于人体肠道、生殖系统内,能产生确切健康功效从而改善宿主微生态平衡、发挥有益作用的活性微生物的总称。益生菌与人体免疫、代谢等息息相关,当人体住满足够的益生菌时,人就会处于健康的状态,但是一旦体内菌群失去平衡,比如菌种间比例发生大幅变化或者超出正常数值时,那么人体就会处于亚健康甚至疾病状态。
膳食纤维是是一种多糖。可溶性膳食纤维在胃肠道内和淀粉等碳水化合物交织在一起,并延缓后者的吸收,故可以起到降低餐后血糖的作用;不可溶性膳食纤维可促进人体胃肠道蠕动,加快食物通过胃肠道,减少吸收;大肠中的不可溶性纤维还可以吸收水分软化大便,从而防治便秘。
与现有技术相比,本发明具有以下有益效果:
(1)从调节胃肠功能途径出发,改善人体代谢紊乱状态,可显著改善人体高血压、高血脂、高血糖等的病症。
(2)本发明的组合物还采用“3+3+3”模式,即前三日服用芦荟胶囊,排毒润肠;中三日服用消化酶和膳食纤维,清除宿便、调节肠道环境;后三日服用益生菌和膳食纤维,定植有益菌、改善胃肠功能;从而可充分发挥各组合物的有益性能,调节人体的代谢功能。
(2)副作用较小,高效安全;本品组合物属于保健品领域,组合物多以对人类身体有益物质为原料,作为一种日常服用的改善人体代谢紊乱的保健食品组合服用疗法,改善人体代谢紊乱的同时还可以起到降低“三高”保健的作用,若干服用疗程后,可显著降低高血压、高血脂,从而降低心脑血管疾病的发生,对于高血糖未患有糖尿病的人群,可预防糖尿病的发生,降低血糖,改善身体亚健康状态。
具体实施方式
下面结合具体实施例对本发明做进一步说明。
实施例1
一种用于改善人体代谢紊乱状态的组合物,以芦荟胶囊、消化酶、益生菌、膳食纤维为主要成分;
其中,芦荟胶囊按以下重量份数配比:芦荟粉5份;大豆油0.5份;蜂蜡0.3份;二氧化钛0.2份;柠檬黄0.2份;明胶0.7份;甘油0.4份;
按以下方法制备:
1)按配方量将芦荟粉、大豆油、蜂蜡、二氧化钛、柠檬黄、明胶、甘油依次置于无菌混合机内,混合均匀;
2)使用全自动胶囊充填机充填步骤1)完成后的混合物,填充好的胃溶胶囊使用胶囊抛光机清除吸附在胶囊外壁上的细粉,使胶囊光洁,无菌下包装。
消化酶按如下重量份数配比:淀粉酶7份;蛋白酶9份;乳糖酶10份;蔗糖酶10份;麦芽糖酶13份;脂肪酶15份;纤维素酶22份;果糖3份;葡萄糖2.5份;硫酸镁0.3份;二氧化硅0.3份;柠檬酸0.2份;苹果香精0.3份;
益生菌按如下重量份数配比:干酪乳杆菌4份;瑞士乳杆菌4份;乳双歧杆菌4份;长双歧杆菌4份;青春双歧杆菌4份;
膳食纤维由以下重量份数的原料制备:大豆膳食纤维9份;麦麸6份;苹果果胶2份;
消化酶、益生菌和膳食纤维通过以下方法制备而成:
1)按配方量将原料依次置于无菌混合机内,混合均匀;
2)使用全自动胶囊充填机充填步骤1)完成后的混合物,填充好的肠溶胶囊使用胶囊抛光机清除吸附在胶囊外壁上的细粉,使胶囊光洁,无菌下包装。
前三日,每日晚饭后服用一次芦荟胶囊,每次40℃以下温水服用1.5g;中三日,每日晚饭后服用一次消化酶和一次膳食纤维,每次40℃以下温水服用各5g;后三日,每日间隔6~8小时服用一次益生菌和一次膳食纤维,每次40℃以下温水服用各2g;选择30例“三高”患者,清淡饮食,每月一个疗程,坚持三个月后,有17例患者血糖、血脂、血压恢复正常水平;坚持六个月后,有23例患者血糖、血脂、血压恢复正常水平。
实施例2
一种用于改善人体代谢紊乱状态的组合物,以芦荟胶囊、消化酶、益生菌、膳食纤维为主要成分;
其中,芦荟胶囊按以下重量份数配比:芦荟粉4份;大豆油0.5份;蜂蜡0.2份;二氧化钛0.3份;柠檬黄0.3份;明胶0.5份;甘油0.2份;
按以下方法制备:
1)按配方量将芦荟粉、大豆油、蜂蜡、二氧化钛、柠檬黄、明胶、甘油依次置于无菌混合机内,混合均匀;
2)使用全自动胶囊充填机充填步骤1)完成后的混合物,填充好的胃溶胶囊使用胶囊抛光机清除吸附在胶囊外壁上的细粉,使胶囊光洁,无菌下包装。
消化酶按如下重量份数配比:淀粉酶6份;蛋白酶9份;乳糖酶7份;蔗糖酶9份;麦芽糖酶13份;脂肪酶13份;纤维素酶21份;果糖2份;葡萄糖2.5份;硫酸镁0.3份;二氧化硅0.3份;柠檬酸0.2份;苹果香精0.2份;
益生菌按如下重量份数配比:罗伊氏乳杆菌5份;干酪乳杆菌5份;长双歧杆菌5份;青春双歧杆菌5份;婴儿双歧杆菌5份;
膳食纤维由以下重量份数的原料制备:大豆膳食纤维10份;麦麸4份;苹果果胶2份;
消化酶、益生菌和膳食纤维通过以下方法制备而成:
1)按配方量将原料依次置于无菌混合机内,混合均匀;
2)使用全自动胶囊充填机充填步骤1)完成后的混合物,填充好的肠溶胶囊使用胶囊抛光机清除吸附在胶囊外壁上的细粉,使胶囊光洁,无菌下包装。
前三日,每日晚饭后服用一次芦荟胶囊,每次40℃以下温水服用1.5g;中三日,每日晚饭后服用一次消化酶和一次膳食纤维,每次40℃以下温水服用各5g;后三日,每日间隔6~8小时服用一次益生菌和一次膳食纤维,每次40℃以下温水服用各2g;选择27例“三高”患者,清淡饮食,每月一个疗程,坚持三个月后,有15例患者血糖、血脂、血压恢复正常水平;坚持六个月后,有23例患者血糖、血脂、血压恢复正常水平。
实施例3
一种用于改善人体代谢紊乱状态的组合物,以芦荟胶囊、消化酶、益生菌、膳食纤维为主要成分;
其中,芦荟胶囊按以下配方量制备:芦荟粉5份;大豆油0.6份;蜂蜡0.3份;二氧化钛0.2份;柠檬黄0.2份;明胶0.5份;甘油0.2份;
按以下方法制备:
1)按配方量将芦荟粉、大豆油、蜂蜡、二氧化钛、柠檬黄、明胶、甘油依次置于无菌混合机内,混合均匀;
2)使用全自动胶囊充填机充填步骤1)完成后的混合物,填充好的胃溶胶囊使用胶囊抛光机清除吸附在胶囊外壁上的细粉,使胶囊光洁,无菌下包装。
消化酶按如下重量份数配比:淀粉酶7份;蛋白酶9份;乳糖酶10份;蔗糖酶10份;麦芽糖酶13份;脂肪酶15份;纤维素酶22份;果糖3份;葡萄糖2.5份;硫酸镁0.3份;二氧化硅0.3份;柠檬酸0.2份;苹果香精0.3份;
益生菌按如下重量份数配比:嗜酸乳杆菌5份;罗伊氏乳杆菌5份;乳双歧杆菌5份;长双歧杆菌5份;青春双歧杆菌5份;
膳食纤维由以下重量份数的原料制备:大豆膳食纤维10份;麦麸6份;苹果果胶3份;
消化酶、益生菌和膳食纤维通过以下方法制备而成:
1)按配方量将原料依次置于无菌混合机内,混合均匀;
2)使用全自动胶囊充填机充填步骤1)完成后的混合物,填充好的肠溶胶囊使用胶囊抛光机清除吸附在胶囊外壁上的细粉,使胶囊光洁,无菌下包装。
前三日,每日晚饭后服用一次芦荟胶囊,每次40℃以下温水服用1.5g;中三日,每日晚饭后服用一次消化酶和一次膳食纤维,每次40℃以下温水服用各5g;后三日,每日间隔6~8小时服用一次益生菌和一次膳食纤维,每次40℃以下温水服用各2g;选择28例“三高”患者,清淡饮食,每月一个疗程,坚持三个月后,有21例患者血糖、血脂、血压恢复正常水平;坚持六个月后,有25例患者血糖、血脂、血压恢复正常水平。
将本实施例中制备的降低高血压、高血糖和高血脂的组合物用于动物验证试验,如实施例4。
实施例4
1、实验目的
通过不同疾病模型小鼠饲喂实验,验证本发明组合物对小鼠血糖、血压、血脂的影响;
2、实验材料与试剂
2.1主要试剂
四氧嘧啶、生理盐水、丙酸睾丸酮、本发明实施例3制备的组合物
3、实验动物
ICR小鼠,体重22.5±4.1g,雌性35只,雄性35只;
ICR小鼠:主要用于安全评价、药理学,毒理学、感染及免疫学实验等,实验室中广泛使用的动物,具有繁殖力好,对疾病的抵抗力强的特点。
4、实验性小鼠模型制备
4.1四氧嘧啶注射法制备糖尿病小鼠模型
将20只ICR小鼠(雌雄比1:1)适应性喂养1周后,禁食24h(不禁水),将四氧嘧啶用生理盐水配制成2%的溶液,以200mg/kg的剂量给小鼠进行腹腔注射,注射四氧嘧啶之后,即恢复小鼠的进食,并观察和记录小鼠的行为变化以及死亡情况,于48h再禁食(不禁水)12h,尾尖取血,用血糖仪测定小鼠的空腹血糖值,选择10只血糖含量大于11.1mmol/L的小鼠(雌雄比1:1)作为糖尿病模型鼠进行验证实验。
4.2丙酸睾丸酮注射法制备高血压小鼠模型
将20只ICR小鼠(雌雄比1:1)适应性喂养1周后,连续测定3天正常血压并记录,第4天起,每日皮下注射丙酸睾酮0.7mg/次,连续2周,观察和记录小鼠的行为变化以及死亡情况,取10只收缩压升高至15mmHg以上的小鼠(雌雄比1:1)用于验证实验。
4.3建立高血脂小鼠模型
将20只ICR小鼠(雌雄比1:1)适应性喂养1周后,禁食24h(不禁水),按照78.8%基础饲料、1%胆固醇、10%蛋黄粉、10%猪油、0.2%胆盐配制高脂饲料,连续饲喂30日,每隔10天尾尖取血,检测小鼠总胆固醇(TC)、甘油三酯(TG)和低密度脂蛋白胆固醇(LDL-C)浓度变化,选取升高最显著的10只作为高血脂小鼠(雌雄比1:1)进行验证实验。
5、实验分组及鉴定指标
实验分组:以正常ICR小鼠为对照组,高血糖、高血压和高血脂疾病模型小鼠为实验组,每组10只小鼠(雌雄比1:1),五组均正常喂料,9日内,前3日每日灌胃芦荟胶囊一次,0.5mg每次;中三日,每日灌胃消化酶和膳食纤维1次,各1mg每次;后三日,每日灌胃益生菌和膳食纤维二次,各1mg每次;
检测指标:以小鼠血糖变化为高血糖组检测指标;以小鼠体重、血压、心率变化为高血压组检测指标;以小鼠总胆固醇(TC)、甘油三酯(TG)和低密度脂蛋白胆固醇(LDL-C)为高血脂组检测指标。
6、实验结果
6.1本发明组合物对高血糖模型小鼠的影响
饲喂前尾尖采血测定小鼠血糖值,连续饲喂九日后再次测定,比较饲喂九日前后血糖值变化可知,正常组小鼠血糖值饲喂前后无显著变化,高血糖组小鼠血糖值较饲喂前显著降低(P<0.05)。
表1本发明组合物对实验小鼠血糖的影响
注:“*”表示P<0.05(饲喂后vs.饲喂前);
6.2本发明组合物对高血压模型小鼠的影响
饲喂前测定小鼠体重、收缩压、心率,连续饲喂九日后再次测定,比较饲喂九日前后体重、血压、心率变化可知,正常组小鼠各检测值无显著变化,高血压小鼠心率和血压值较饲喂前显著降低(P<0.05)。
表2本发明组合物对实验小鼠血压的影响
注:“*”表示P<0.05(饲喂后vs.饲喂前);
6.3本发明组合物对高血脂模型小鼠的影响
饲喂前测定小鼠总胆固醇(TC)、甘油三酯(TG)和低密度脂蛋白胆固醇(LDL-C),连续饲喂九日后再次测定,比较饲喂九日前后TC、TG、LDL-C变化可知,正常组小鼠各检测值无显著变化,高血脂小鼠TC、TG较饲喂前显著降低(P<0.01,P<0.05)。
表3本发明组合物对实验小鼠血脂的影响
注:“*”表示P<0.05(饲喂后vs.饲喂前);“**”表示P<0.01(饲喂后vs.饲喂前);
上述实施方式仅为本发明的优选实施方式,不能以此来限定本发明保护的范围,本领域的技术人员在发明的基础上所做的任何非实质性的变化及替换均属于本发明所要求保护的范围。
Claims (10)
1.一种用于改善人体代谢紊乱状态的组合物,其特征在于,包括:芦荟胶囊、消化酶、益生菌、膳食纤维。
2.根据权利要求1所述一种用于改善人体代谢紊乱状态的组合物,其特征在于,所述组合物服用方法为前三日服用所述芦荟胶囊、中三日服用所述消化酶和所述膳食纤维,后三日服用所述益生菌和所述膳食纤维。
3.根据权利要求1所述的一种用于改善人体代谢紊乱状态的组合物,其特征在于,所述芦荟胶囊包括以下重量份数的原料:芦荟粉3~5份;大豆油0.5~1份;蜂蜡0.1~0.5份;二氧化钛0.1~0.5份;柠檬黄0.2~0.4份;明胶0.5~0.7份;甘油0.2~0.5份。
4.根据权利要求1所述的一种用于改善人体代谢紊乱状态的组合物,其特征在于,所述芦荟胶囊包括以下重量份数的原料:芦荟粉5份;大豆油0.5份;蜂蜡0.3份;二氧化钛0.2份;柠檬黄0.2份;明胶0.7份;甘油0.4份。
5.根据权利要求1所述的一种用于改善人体代谢紊乱状态的组合物,其特征在于,所述消化酶包括以下重量份数的原料:淀粉酶4~7份;蛋白酶5~9份;乳糖酶6~10份;蔗糖酶6~10份;麦芽糖酶11~14份;脂肪酶13~15份;纤维素酶20~23份;果糖1~3份;葡萄糖1~2.5份;硫酸镁0.2~0.5份;二氧化硅0.3~0.5份;柠檬酸0.1~0.3份;苹果香精0.2~0.4份。
6.根据权利要求1所述的一种用于改善人体代谢紊乱状态的组合物,其特征在于,所述消化酶包括以下重量份数的原料:淀粉酶7份;蛋白酶9份;乳糖酶10份;蔗糖酶10份;麦芽糖酶13份;脂肪酶15份;纤维素酶22份;果糖3份;葡萄糖2.5份;硫酸镁0.3份;二氧化硅0.3份;柠檬酸0.2份;苹果香精0.3份。
7.根据权利要求1所述的一种用于改善人体代谢紊乱状态的组合物,其特征在于,所述益生菌为:嗜酸乳杆菌3~5份;罗伊氏乳杆菌3~5份;干酪乳杆菌3~5份;瑞士乳杆菌3~5份;乳双歧杆菌3~5份;长双歧杆菌3~5份;青春双歧杆菌3~5份;婴儿双歧杆菌3~5份中的任意五种,其中,益生菌活菌量为109~1011CFU/g。
8.根据权利要求1所述的一种用于改善人体代谢紊乱状态的组合物,其特征在于,所述益生菌包括以下重量份数的原料:干酪乳杆菌4份;瑞士乳杆菌4份;乳双歧杆菌4份;长双歧杆菌4份;青春双歧杆菌4份。
9.根据权利要求1所述的一种用于改善人体代谢紊乱状态的组合物,其特征在于,所述膳食纤维包括以下重量份数的原料:大豆膳食纤维5~10份;麦麸4~7份;苹果果胶2~3份的成分混合。
10.一种制备权利要求1-9任一项所述的用于改善人体代谢紊乱状态的组合物的方法,其特征在于,包括如下步骤:
(1)原料混合物制备:分别将各组合物中原料按配方依次置于无菌混合机内,混合均匀,即得所述原料混合物;
(2)胶囊制备:使用全自动胶囊充填机充填步骤(1)中所述原料混合物,填充好的胃溶胶囊使用胶囊抛光机清除吸附在胶囊外壁上的细粉,使胶囊光洁,无菌下包装,即制成所述组合物胶囊。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611146933.7A CN106666738A (zh) | 2016-12-13 | 2016-12-13 | 一种用于改善人体代谢紊乱状态的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611146933.7A CN106666738A (zh) | 2016-12-13 | 2016-12-13 | 一种用于改善人体代谢紊乱状态的组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106666738A true CN106666738A (zh) | 2017-05-17 |
Family
ID=58868333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611146933.7A Pending CN106666738A (zh) | 2016-12-13 | 2016-12-13 | 一种用于改善人体代谢紊乱状态的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106666738A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107373661A (zh) * | 2017-06-20 | 2017-11-24 | 山西趣动健康科技有限公司 | 一种纤维素代餐粉 |
JP2020007284A (ja) * | 2018-07-11 | 2020-01-16 | 雪印メグミルク株式会社 | 食後血糖値上昇抑制用組成物及びその製造方法 |
US11541082B2 (en) * | 2017-06-05 | 2023-01-03 | Probi Ab | Microbial compositions |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1348343A1 (de) * | 2002-03-28 | 2003-10-01 | PM-International AG | Nahrungsergänzungsmittelpräparat |
CN103764154A (zh) * | 2011-06-10 | 2014-04-30 | 普洛特拉有限公司 | 包含片球菌属的药物组合物和减轻胃肠综合征的症状的方法 |
CN104740138A (zh) * | 2013-12-31 | 2015-07-01 | 深圳华大基因科技有限公司 | 包含芦荟、益生菌和益生元的组合物及其用途 |
AU2015100952A4 (en) * | 2014-07-17 | 2015-08-20 | Pharm-A-Care Laboratories Pty Ltd | Probiotic- and enzyme-containing compositions and uses thereof |
CN105053778A (zh) * | 2015-08-23 | 2015-11-18 | 洛阳维尔健生物工程有限公司 | 润肠通便的芦荟低聚木糖软胶囊及其制备方法 |
-
2016
- 2016-12-13 CN CN201611146933.7A patent/CN106666738A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1348343A1 (de) * | 2002-03-28 | 2003-10-01 | PM-International AG | Nahrungsergänzungsmittelpräparat |
CN103764154A (zh) * | 2011-06-10 | 2014-04-30 | 普洛特拉有限公司 | 包含片球菌属的药物组合物和减轻胃肠综合征的症状的方法 |
CN104740138A (zh) * | 2013-12-31 | 2015-07-01 | 深圳华大基因科技有限公司 | 包含芦荟、益生菌和益生元的组合物及其用途 |
AU2015100952A4 (en) * | 2014-07-17 | 2015-08-20 | Pharm-A-Care Laboratories Pty Ltd | Probiotic- and enzyme-containing compositions and uses thereof |
CN105053778A (zh) * | 2015-08-23 | 2015-11-18 | 洛阳维尔健生物工程有限公司 | 润肠通便的芦荟低聚木糖软胶囊及其制备方法 |
Non-Patent Citations (2)
Title |
---|
佚名: "联合立邦芦荟软胶囊效果如何", 《HTTPS://WENDA.SO.COM/Q/1399161999128588》 * |
佚名: "芦荟大豆膳食纤维胶囊", 《HTTPS://BAIKE.SO.COM/DOC/7480118-7749267.HTML》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11541082B2 (en) * | 2017-06-05 | 2023-01-03 | Probi Ab | Microbial compositions |
CN107373661A (zh) * | 2017-06-20 | 2017-11-24 | 山西趣动健康科技有限公司 | 一种纤维素代餐粉 |
JP2020007284A (ja) * | 2018-07-11 | 2020-01-16 | 雪印メグミルク株式会社 | 食後血糖値上昇抑制用組成物及びその製造方法 |
JP7219026B2 (ja) | 2018-07-11 | 2023-02-07 | 雪印メグミルク株式会社 | 食後血糖値上昇抑制用組成物及びその製造方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101911205B1 (ko) | 배변유도 및 다이어트용 조성물과 이의 제조방법 | |
CN107496850B (zh) | 一种调节肠道微生态制剂的配方及应用 | |
CN105995976A (zh) | 一种具有降脂减肥作用的综合酵素粉及其应用 | |
CN106174585A (zh) | 降血糖的组合物及降血糖的复合益生菌特膳食品 | |
CN103082292A (zh) | 罗斯氏菌(Roseburia)在治疗和预防肥胖相关疾病中的应用 | |
CN101683477A (zh) | 一种用于减肥的组合物 | |
CN110623182A (zh) | 一种用于治疗高尿酸及痛风的益生菌植物固体饮料 | |
CN112716982A (zh) | 含乳酸菌的组合物及其用途 | |
CN109315769A (zh) | 一种用于改善人体肠内环境的组合物及其制备方法 | |
CN104489462A (zh) | 一种低聚木糖益生菌粉 | |
CN108771247A (zh) | 一种具有润肠通便功能的膳食纤维制品及其制备方法 | |
CN106666738A (zh) | 一种用于改善人体代谢紊乱状态的组合物及其制备方法 | |
CN111543605A (zh) | 一种四高或肥胖人群用综合营养粉 | |
CN107334156A (zh) | 催乳全营养配方食品 | |
CN113750113B (zh) | 一种益生菌和益生元的组合物及其应用 | |
CN110710660A (zh) | 含有苦瓜粉的降低血糖组合物及膳食补充剂 | |
CN110075226A (zh) | 一种可以降血脂的益生菌组合物 | |
CN109043553A (zh) | 一种妊娠糖尿病患者食用的特殊食品及其制备方法 | |
Tabrizi et al. | Functional laxative foods: Concepts, trends and health benefits | |
KR102000170B1 (ko) | 체지방 감소 및 장관면역활성 증진을 위한 건강보조식품 | |
CN108523123A (zh) | 一种糖尿病全营养支持食品 | |
CN103920140B (zh) | 一种人用降糖减肥降脂复方制剂 | |
CN109043555A (zh) | 一种高血糖患者食用的特殊食品及其制备方法 | |
CN110638842A (zh) | 一种改善高血糖的益生菌组合物 | |
CN110050972B (zh) | 芦荟山楂球及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170517 |